Literature summary for 1.14.14.32 extracted from

Toren, P.J.; Kim, S.; Pham, S.; Mangalji, A.; Adomat, H.; Guns, E.S.; Zoubeidi, A.; Moore, W.; Gleave, M.E.
Anticancer activity of a novel selective CYP17A1 inhibitor in preclinical models of castrate-resistant prostate cancer (2015), Mol. Cancer Ther., 14, 59-69 .

Search for more literature for 1.14.14.32

Application

Application	Comment	Organism
medicine	inhibitor VT-464 displays selective suppression of androgen synthesis through CYP17 lyase inhibition. VT-464 shows a greater decrease in androgen receptor transactivation than inhibitor abiraterone	Homo sapiens

Inhibitors

Inhibitors	Comment	Organism	Structure
VT-464	selective suppression of androgen synthesis through CYP17 lyase inhibition	Homo sapiens

Organism

Organism	UniProt	Comment	Textmining
Homo sapiens	-	-	-

Source Tissue

Source Tissue	Comment	Organism	Textmining
LNCaP cell	-	Homo sapiens	-

Use of this online version of BRENDA is free under the CC BY 4.0 license. See terms of use for full details.

Release 2023.1 (January 2023)